BECAUSE of the recent innovation of the metyrapone test as a measure of endogenous ACTH reserve,1,2 methodological variations on this technique have not been clarified. The dosage, route, and time of day the drug is administered are as important to the final result of the test as is the selection of the appropriate steroid analytical procedures.3 The paucity of reports concerning use of the intravenous route of administration and the current controversy over the results even in normal individuals 4 prompt us to report our experience.This study documents the findings in control subjects and in patients with chromophobe adenoma of the pituitary gland. Increments in the total urinary Porter-Silber chromogens which occurred after the administration of intravenous metyrapone were employed as an indirect measure of pituitary adrenocorticotrophic hormone (ACTH) reserve.
Materials and Methods
Thirteen control subjects and eighteen patients with chromophobe adenoma seen at The University
MIN BS, COLE VW. Intravenous Metyrapone Test in Chromophobe Adenoma. Arch Intern Med. 1965;116(4):581–585. doi:10.1001/archinte.1965.03870040095019
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: